Press Releases March 25, 2026 08:00 AM

Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”

Kestra Medical Technologies Named Finalist for 2026 GeekWire 'Deal of the Year' for Its Successful 2025 IPO

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
KMTS

Kestra Medical Technologies, a wearable medical device and digital healthcare firm, has been named a finalist in the 'Deal of the Year' category at the 2026 GeekWire Awards. The nomination recognizes Kestra's impactful 2025 initial public offering, which bolstered the company’s capacity to expand commercially and innovate its Cardiac Recovery System® platform. This accolade underscores Kestra's growing momentum in the Pacific Northwest technology ecosystem.

Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
KMTS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kestra Medical Technologies secured a finalist position for the 'Deal of the Year' at the upcoming 2026 GeekWire Awards.
  • The recognition highlights Kestra's successful 2025 IPO, which supports growth and innovation in cardiovascular monitoring and therapeutic technology.
  • Kestra focuses on transforming cardiovascular disease patient outcomes with wearable devices and connected digital healthcare solutions.

KIRKLAND, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it has been named a finalist in the “Deal of the Year” category for the 2026 GeekWire Awards. Now in its 15th year, the annual awards recognize companies and leaders shaping the Pacific Northwest technology ecosystem, where Kestra continues to expand its presence.

The “Deal of the Year” category recognizes impactful transactions including acquisitions, financings, and public offerings. Kestra was named a finalist for its successful 2025 initial public offering, a milestone that supports continued commercial expansion and innovation across its Cardiac Recovery System® platform.

“This recognition highlights the momentum we’re building as we scale Kestra,” said Brian Webster, President and Chief Executive Officer. “Our IPO strengthened our ability to invest in growth and accelerate our progress toward a new standard of care for patients at risk of sudden cardiac arrest.”

Finalists were selected through a multi-stage nomination and judging process involving the regional technology community. Community voting is open through April 16, 2026, and winners will be announced at the GeekWire Awards ceremony on May 7, 2026, in Seattle. To vote, visit: https://www.surveymonkey.com/r/BJQ2PM9

About Kestra 
Kestra Medical Technologies is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. 


Risks

  • The company’s future growth depends on continued successful execution and market acceptance of its Cardiac Recovery System®, which may face competition or regulatory hurdles.
  • The wearable medical device sector is highly competitive and subject to rapid technological changes that could impact Kestra’s market position.
  • Delays in adoption or reimbursement challenges for novel medical devices could impact Kestra's commercial expansion plans.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026